HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application

Executive Summary

Perrigo's HRA Pharma submits to FDA on 11 July an NDA by for OTC 0.075-mg norgestrel, branded Opill, The same formulation previously was available Rx 30 years. 

You may also be interested in...



US Consumer Health Industry In 2023: Monograph Results, Switch Hopes On OTC Drug Sector Radar

OTC drug and dietary supplement industry trade group executives discuss questions on potential market and regulatory developments affecting their members’ businesses. HBW Insight reports on OTC drug sector’s outlook for the FDA potentially publishing a final rule to expand switch opportunities as well as its anticipation of marketplace results from monograph program overhaul.

'Catch-Up’ Symptoms Slow Perrigo In Cold Season

Strong cough/cold season forecast bodes well for upper respiratory and other OTCs Perrigo provides as private label and store brand products, but it isn’t expecting to capitalize in the Americas due to lingering impacts from supply chain and production disruptions linked to the COVID-19 pandemic.

Healthcare Professionals In Spain Call On Government To Switch Contraceptive Pill

Representatives of doctors and pharmacists have met with the director of the Spanish Agency for Medicines and Medical Devices to discuss a position paper which argues enabling OTC access to the daily contraceptive pill will empower women to manage their own reproductive health and improve family planning.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152712

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel